Allegra® is the original reference brand name, while the marketed domestic generic product in China is Minfeile®. It is a second‑generation non‑sedating H1 antihistamine. It selectively blocks peripheral H1 histamine receptors to relieve allergic symptoms without significant penetration into the central nervous system.
Main Indications
For the treatment of seasonal allergic rhinitis and chronic idiopathic urticaria in children aged 6 months and older.
Clinical Research
Clinical trials showed that fexofenadine effectively relieves sneezing, rhinorrhea, nasal itching and pruritus of urticaria. The dry suspension formulation is convenient for paediatric patients who cannot swallow tablets. It has minimal sedative effects and does not cause obvious cardiac QT prolongation at recommended doses.
Common Side Effects
Systemic reactions: fatigue, drowsiness;
Common mild adverse reactions: headache, nausea, dry mouth. Rare serious adverse events: hypersensitivity reactions.
Approval Status in China
This domestic generic drug, marketed under brand name Minfeile® (reference brand name Allegra®), was officially approved for marketing in China in 2023, with the specification of 30mg per sachet. It is currently a prescription anti-allergy drug.
Buy Allegra (Fexofenadine Hydrochloride for Suspension) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
